03.07.25 -- Survey Findings: How Are IDMP Readiness Efforts Progressing?

What is the curative potential of protein design? Marc Lajoie, CEO at Outpace Bio, discusses how de novo proteins can be used to reprogram immune cells. 

Oncolytic virus (OV) While oncolytic virus (OV) therapy holds significant promise, addressing immunological challenges and navigating the evolving regulatory environment are critical for its success.

AI applications in medical writing are in their infancy, and the technology suffers several shortcomings including plagiarism, copyright infringement, and misinformation dissemination.

Explore the significance of targeted therapies and adaptive trial designs that prioritize patient-specific characteristics.

A regulatory expert provides her insight on what regulatory experts do and how they can help you accelerate your path from bench to clinic.

Explore how therapeutic area (TA) datasets can be leveraged to address the challenges multiple myeloma (MM) presents in the field of hematologic malignancies.

Improve patient engagement and data accuracy through the use of an ePRO platform with interactive visual representations.

What should you look for when searching for the right vendor to help you maintain security of raw materials and how can you establish communication that builds confidence?

Although polymer bags are an excellent choice for cold chain use, not all polymer films perform the same way, even if their specifications rate them for use at low temperatures.